Lifecore Biomedical, Inc.
General ticker "LFCR" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $239.8M (TTM average)
Lifecore Biomedical, Inc. does not follow the US Stock Market performance with the rate: -21.1%.
Estimated limits based on current volatility of 2.8%: low 3.99$, high 4.21$
Factors to consider:
- Total employees count: 406 (-22.5%) as of 2025
- Top business risk factors: Internal control weaknesses, Operational and conduct risks, Customer concentration, Regulatory and compliance, Labor/talent shortage/retention
- Earnings for 12 months up through Q4 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-05-25 to 2027-05-25
- 2025-05-25 to 2026-05-25 estimated range: [4.87$, 9.92$]
- 2026-05-25 to 2027-05-25 estimated range: [4.35$, 9.08$]
Financial Metrics affecting the LFCR estimates:
- Positive: with PPE of -5.1 at the end of fiscal year the price was neutral
- Negative: Operating cash flow per share per price, % of -0.09 <= 2.37
- Negative: Shareholder equity ratio, % of 0.56 <= 7.04
- Positive: -13.52 < Operating profit margin, % of -11.80
- Positive: Industry inventory ratio change (median), % of -0.42 <= -0.33
- Positive: -51.61 < Industry operating profit margin (median), % of -22.57
- Negative: Industry earnings per price (median), % of 0 <= 0
- Negative: Investing cash flow per share per price, % of -2.74 <= -2.60
- Negative: 4.56 < Interest expense per share per price, % of 9.34
- Positive: -6.44 < Industry operating cash flow per share per price (median), % of -2.99
Short-term LFCR quotes
Long-term LFCR plot with estimates
Financial data
| YTD | 2023-05-28 | 2024-05-26 | 2025-05-25 |
|---|---|---|---|
| Operating Revenue | $105.38MM | $128.26MM | $128.87MM |
| Operating Expenses | $127.17MM | $137.10MM | $146.11MM |
| Operating Income | $-21.80MM | $-8.84MM | $-17.25MM |
| Non-Operating Income | $-42.13MM | $18.36MM | $-21.43MM |
| Interest Expense | $17.65MM | $18.09MM | $21.84MM |
| R&D Expense | $8.74MM | $8.57MM | $8.26MM |
| Income(Loss) | $-63.93MM | $9.51MM | $-38.67MM |
| Taxes | $0.31MM | $0.18MM | $0.04MM |
| Other Income(Loss) | $-35.33MM | $2.68MM | $0.00MM |
| Net Income(Loss)* | $-99.56MM | $12.01MM | $-38.72MM |
| Stockholders Equity | $-4.23MM | $11.31MM | $1.34MM |
| Inventory | $40.84MM | $39.98MM | $32.29MM |
| Assets | $253.54MM | $253.96MM | $239.34MM |
| Operating Cash Flow | $-17.44MM | $0.26MM | $-0.21MM |
| Capital expenditure | $21.48MM | $18.39MM | $13.41MM |
| Investing Cash Flow | $-4.81MM | $-18.39MM | $-6.42MM |
| Financing Cash Flow | $39.70MM | $7.51MM | $6.42MM |
| Earnings Per Share** | $-3.32 | $0.39 | $-1.11 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.